The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent device having a low driving voltage and/or a high luminous efficiency and/or a long lifespan can be provided, by comprising an organic electroluminescent compound according to the present disclosure.

The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent device having a low driving voltage and/or a high luminous efficiency and/or a long lifespan can be provided, by comprising an organic electroluminescent compound according to the present disclosure.

Provided are a novel compound and an organic electronic device using the same. The novel compound is represented by the following Formula (I): ##STR00001## wherein X.sup.1 and X.sup.2 are each independently C(R.sup.a), multiple (R.sup.a)s are the same or different, and the two (R.sup.a)s are joined together to form an aryl ring; wherein X.sup.3 and X.sup.4 are each independently C(R.sup.b), multiple (R.sup.b)s are the same or different, and the two (R.sup.b)s are joined together to form a polycyclic aromatic ring.

Provided are a novel compound and an organic electronic device using the same. The novel compound is represented by the following Formula (I): ##STR00001## wherein X.sup.1 and X.sup.2 are each independently C(R.sup.a), multiple (R.sup.a)s are the same or different, and the two (R.sup.a)s are joined together to form an aryl ring; wherein X.sup.3 and X.sup.4 are each independently C(R.sup.b), multiple (R.sup.b)s are the same or different, and the two (R.sup.b)s are joined together to form a polycyclic aromatic ring.

Provided herein are inhibitors of transmembrane protein 16A (TMEM 16A), a Ca.sup.2+-activated CI channel expressed widely in mammalian epithelia, as well as in vascular smooth muscle and some tumors and electrically excitable cells. TMEM16A inhibitors have potential utility for treatment or management of disorders of epithelial fluid and mucus secretion, hypertension, some cancers, pain, and other diseases.

Provided herein are inhibitors of transmembrane protein 16A (TMEM 16A), a Ca.sup.2+-activated CI channel expressed widely in mammalian epithelia, as well as in vascular smooth muscle and some tumors and electrically excitable cells. TMEM16A inhibitors have potential utility for treatment or management of disorders of epithelial fluid and mucus secretion, hypertension, some cancers, pain, and other diseases.

The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound of the present disclosure, an organic electroluminescent device having improved driving voltage, luminous efficiency, and/or lifespan characteristics can be provided.

The present invention relates to a new class of compounds of formula (I) having an antiviral effect and the uses thereof.

Disclosed herein are novel cycloalka[b]heteroaryl compounds having CX3CR1/fractalkine receptor (CX3CR1) agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with CX3CR1 receptor activity in animals, in particular humans.

Provided are a novel compound and an organic electronic device using the same. The novel compound is represented by the following Formula (I): ##STR00001## wherein X.sup.1 and X.sup.2 are each independently C(R.sup.a), the two (R.sup.a)s are the same or different, and the two (R.sup.a)s are joined together to form an aryl ring; X.sup.3 and X.sup.4 are each independently C(R.sup.b), the two (R.sup.b)s are the same or different, and the two (R.sup.b)s are joined together to form a heteroaryl ring containing at least one furan group or at least one thiophene group.